Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects between the ages of 18 and 75 years, inclusive~* Must have moderate-to-severe, active Rheumatoid Arthritis~* Must have had an inadequate response to Methotrexate~* Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated~Exclusion Criteria~* Subjects with any acute or chronic infections or infection history~* Have acute or active chronic dermatological disorders prior to study start~* Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study~* Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency~* Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06651600 (Type: EXPERIMENTAL): Study Drug
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).